BrightGene Bio-Medical
博瑞医药
Executive Summary
BrightGene Bio-Medical is a Suzhou-based CDMO trading on Shanghai's STAR Market with ~$180M revenue and strong profitability (15% net margin). The company faces medium BIOSECURE risk due to congressional pressure but has not been formally designated, creating deal uncertainty for US partners. Recent regulatory filings suggest active fundraising and governance strengthening, indicating potential deal readiness for partnerships requiring manufacturing scale.
Structure: BrightGene appears to be a straightforward Chinese domestic corporation listed on Shanghai STAR Market without apparent VIE structure complexity. The frequent regulatory filings around fund usage and non-operating capital relationships suggest a relatively transparent corporate structure, though detailed subsidiary mapping would be required for comprehensive due diligence.
Latest Financials
Revenue: 1282551614.5, Net Profit: 189166937.36. Source: East Money (688166)
Period: 2024-12-31 | Source: eastmoney
Corporate Events
博瑞医药：国联民生证券承销保荐有限公司关于博瑞生物医药（苏州）股份有限公司2025年持续督导跟踪报告
CNINFO announcement for BrightGene Bio-Medical (688166.SS)
博瑞医药：国联民生证券承销保荐有限公司关于博瑞生物医药（苏州）股份有限公司2025年度募集资金存放与使用情况的专项核查报告
CNINFO announcement for BrightGene Bio-Medical (688166.SS)
博瑞医药：关于博瑞生物医药（苏州）股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
CNINFO announcement for BrightGene Bio-Medical (688166.SS)
博瑞医药：2025年年度报告摘要
CNINFO announcement for BrightGene Bio-Medical (688166.SS)
博瑞医药：董事、高级管理人员薪酬管理制度
CNINFO announcement for BrightGene Bio-Medical (688166.SS)
BrightGene Bio-Medical Financial Report
Revenue: 1282551614.5, Net Profit: 189166937.36. Source: East Money (688166)
BIOSECURE Risk
Congressional pressure designation creates regulatory uncertainty but company has not been formally added to BIOSECURE list, leaving room for compliant partnerships
Key Exposures:
- •Congressional scrutiny as Chinese CDMO
- •Potential future BIOSECURE designation
- •Supply chain restrictions for US partners
Mitigation: Unknown - no public statements on BIOSECURE compliance measures identified
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific licensing deals identified, but active regulatory filings suggest ongoing business development
Approach: Approach with caution - conduct thorough BIOSECURE compliance assessment before serious discussions, focus on non-critical manufacturing partnerships if pursuing
Red Flags
- ⚠Congressional BIOSECURE pressure creating regulatory uncertainty
- ⚠Limited public disclosure on key management team
- ⚠No clear subsidiary structure visibility
- ⚠Potential supply chain restrictions for US partnerships
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.